Company News: Page (1) of 1 - 12/14/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

MorphoSys to Present at Upcoming Investor Conferences

(December 14, 2017)

DGAP-News: MorphoSys AG / Key word(s): Conference

14.12.2017 / 16:00
The issuer is solely responsible for the content of this announcement.


Planegg/Munich, Germany, December 14, 2017

MorphoSys to Present at Upcoming Investor Conferences


MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:



J.P. Morgan Annual Healthcare Conference
Date: January 10, 2018, 12:00 pm PST (09:00 pm CET, 8:00 pm GMT)
Venue: San Francisco, CA, USA
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
Jens Holstein, Chief Financial Officer of MorphoSys AG
Dr. Malte Peters, Chief Development Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR

Kepler Cheuvreux German Corporate Conference
Date: January 15, 2018, 2:45 pm CET (8:45 am EST, 1:45 pm GMT)
Venue: Frankfurt, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR

LEERINK Partners 7th Annual Global Healthcare Conference
Date: February 14-15, 2018
Venue: New York, USA
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR

Oddo Seydler German Conference
Date: February 21-22, 2018
Venue: Frankfurt, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR

PDF versions of the presentations will be provided at www.morphosys.com. The link to the webcasts will be filed under www.morphosys.com/conference-calls.

About MorphoSys:
MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Innovative technologies and smart development strategies are central to our approach. Success is created by our people, who focus on excellence in all they do, collaborate closely across disciplines and are driven by a desire to make the medicines of tomorrow a reality. Success benefits all of our stakeholders.
Based on its proprietary technology platforms, particularly in the field of fully human therapeutic antibodies, MorphoSys, together with its partners, has built a pipeline of more than 100 programs in R&D, around a quarter of which are currently in clinical development.
In its proprietary development segment, MorphoSys, alone or with partners, is developing new therapeutic candidates, mainly focusing on cancer and inflammation. In its partnered discovery segment, MorphoSys uses its technologies to discover new drug candidates for pharmaceutical partners and participates in the programs' further development success, through success-based payments and royalties. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
 

For more information, please contact:

MorphoSys AG

Anke Linnartz
Head of Corporate Communications & IR

Jochen Orlowski
Associate Director Corporate Communications & IR

Alexandra Goller
Senior Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
[email protected]
 



14.12.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Page: 1


Related Keywords:

[ServletException in:/common/ads/links.jsp] The absolute uri: http://java.sun.com/jstl/core cannot be resolved in either web.xml or the jar files deployed with this application'

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved